PMID- 26042126
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150604
LR  - 20201226
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 6
DP  - 2015
TI  - Dendritic cell-based vaccination in cancer: therapeutic implications emerging 
      from murine models.
PG  - 243
LID - 10.3389/fimmu.2015.00243 [doi]
LID - 243
AB  - Dendritic cells (DCs) play a pivotal role in the orchestration of immune 
      responses, and are thus key targets in cancer vaccine design. Since the 2010 FDA 
      approval of the first cancer DC-based vaccine (Sipuleucel-T), there has been a 
      surge of interest in exploiting these cells as a therapeutic option for the 
      treatment of tumors of diverse origin. In spite of the encouraging results 
      obtained in the clinic, many elements of DC-based vaccination strategies need to 
      be optimized. In this context, the use of experimental cancer models can help 
      direct efforts toward an effective vaccine design. This paper reviews recent 
      findings in murine models regarding the antitumoral mechanisms of DC-based 
      vaccination, covering issues related to antigen sources, the use of adjuvants and 
      maturing agents, and the role of DC subsets and their interaction in the 
      initiation of antitumoral immune responses. The summary of such diverse aspects 
      will highlight advantages and drawbacks in the use of murine models, and 
      contribute to the design of successful DC-based translational approaches for 
      cancer treatment.
FAU - Mac Keon, Soledad
AU  - Mac Keon S
AD  - Laboratorio de Cancerologia, Fundacion Instituto Leloir, Instituto de 
      Investigaciones Bioquimicas de Buenos Aires IIBBA-CONICET , Buenos Aires , 
      Argentina.
FAU - Ruiz, Maria Sol
AU  - Ruiz MS
AD  - Centro de Investigaciones Oncologicas, Fundacion para la Investigacion, Docencia 
      y Prevencion del Cancer (FUCA) , Buenos Aires , Argentina.
FAU - Gazzaniga, Silvina
AU  - Gazzaniga S
AD  - Laboratorio de Biologia Tumoral, Departamento de Quimica Biologica 
      IQUIBICEN-CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de 
      Buenos Aires , Buenos Aires , Argentina.
FAU - Wainstok, Rosa
AU  - Wainstok R
AD  - Laboratorio de Cancerologia, Fundacion Instituto Leloir, Instituto de 
      Investigaciones Bioquimicas de Buenos Aires IIBBA-CONICET , Buenos Aires , 
      Argentina ; Laboratorio de Biologia Tumoral, Departamento de Quimica Biologica 
      IQUIBICEN-CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de 
      Buenos Aires , Buenos Aires , Argentina.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150520
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC4438595
OTO - NOTNLM
OT  - adjuvants
OT  - cancer immunotherapy
OT  - dendritic cell maturation
OT  - dendritic cell subsets
OT  - dendritic cell-based vaccines
OT  - dendritic cells
EDAT- 2015/06/05 06:00
MHDA- 2015/06/05 06:01
PMCR- 2015/01/01
CRDT- 2015/06/05 06:00
PHST- 2014/12/17 00:00 [received]
PHST- 2015/05/06 00:00 [accepted]
PHST- 2015/06/05 06:00 [entrez]
PHST- 2015/06/05 06:00 [pubmed]
PHST- 2015/06/05 06:01 [medline]
PHST- 2015/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2015.00243 [doi]
PST - epublish
SO  - Front Immunol. 2015 May 20;6:243. doi: 10.3389/fimmu.2015.00243. eCollection 
      2015.